Top Story Today
Sanofi Writes a $1.5 Billion Check for a Chinese Cancer Drug Nobody Saw Coming
Sanofi just locked down exclusive global rights to rovadicitinib, a first-in-class oral drug for myelofibrosis developed by Sino Biopharmaceutical's subsidiary, paying $135 million upfront with up to $1.395 billion in milestones. The drug hits two signaling pathways (JAK and ROCK) simultaneously, already won approval in China, and has Phase III trials underway for graft-versus-host disease. The deal lands amid a massive wave of Chinese biotech out-licensing: $136 billion in total deal value in 2025 alone, more than doubling the prior year. Geopolitics and the BIOSECURE Act haven't slowed the money one bit.
Why it matters: With massive drug revenues facing patent expiration by 2030, Big Pharma's pipeline desperation is turning China's biotech sector from imitator to must-have partner, and no amount of political friction is stopping the checkbooks from opening.
Read more →Regulatory Crackdowns & Clarity
The FDA Just Went After 30 Companies Selling Knockoff Ozempic
Thirty warning letters landed on telehealth companies and compounding pharmacies still selling copycat semaglutide, months after the drug shortage ended and the legal window closed. The FDA cited over 520 adverse event reports, patients accidentally injecting up to 20 times their intended dose, and one company linked to ER visits from contaminated vials. Hims & Hers already pulled its compounded GLP-1 pill. Companies must respond promptly or face potential federal prosecution.
Read more →The FDA Finally Explains How Old Drugs Block Generics for Three Extra Years
A new draft guidance spells out exactly how drugmakers earn three years of generic-free protection for already-approved drugs by running new clinical studies. The document clarifies that qualifying studies must be "essential" to approval, not just confirmatory. For pharma companies weighing costly new-indication trials, this clarity changes the math on whether the investment is worth it.
Read more →The Obesity Race
Lilly's Oral Obesity Pill Has a March 25 FDA Date and $1.5B in Inventory Ready to Ship
Eli Lilly has already stockpiled $1.5 billion worth of orforglipron, an oral obesity pill facing a March 25 FDA decision. In clinical trials, the drug delivered meaningful weight loss across doses. It also beat Novo Nordisk's oral semaglutide head-to-head on blood sugar control in diabetes patients. The pill format could reach millions of patients who refuse weekly injections, and analysts project the combined Lilly obesity franchise could hit $101 billion in peak sales.
Read more →Deals & Strategy
Roche Bets Half a Billion on South Korea as Its Asian Trial Hub
Roche committed up to 710 billion won (approximately $484 million) over five years to South Korea, but the money isn't going to factories. It's funding clinical trials, R&D talent, and local biotech partnerships. Running trials in Korea costs 30 to 40% less than in the U.S., and South Korea's government aims to become a top-tier clinical trial nation.
Read more →Lonza Hands Back the Cell Therapy Tech It Bought Eight Years Ago
Octane Medical Group is reacquiring Lonza's entire personalized medicine business, including the Cocoon Platform that Octane originally built. Lonza bought an 80% stake in 2018 to scale personalized cell therapy manufacturing, but its new "One Lonza" strategy focuses on pure-play large-scale contract manufacturing. Octane gets back its core tech, the customer base, and the workforce; Lonza gets a cleaner portfolio in a fast-growing CDMO market.
Read more →